Camrelizumab Plus Famitinib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 2 Study
Bei Xu, Guopei Zhu, Jin Lu, Ximei Zhang, Xiaozhong Chen, Qinjiang Liu, Song Qu, Jia Fan, Tianshu Liu · 2026
Read Camrelizumab Plus Famitinib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 2 Study by Bei Xu, Guopei Zhu, Jin Lu, Ximei Zhang, Xiaozhong Chen, Qinjiang Liu, Song Qu, Jia Fan, Tianshu Liu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13238771.txt.
Description
Bei Xu and co-authors test a drug pair for head and neck cancer that came back or spread in a 2026 study. Patients whose cancer grew past a first metal-based cure form the group. One drug frees the immune system, and one chokes the tumour's blood feed.
Twenty patients in many hubs took the pair on a set dose clock. The chief score is the share whose tumours shrink in a clear way. Side scores track how long gains hold, how fast they come, and how safe the pair proves.
Catalog record
| CREATOR | Bei Xu, Guopei Zhu, Jin Lu, Ximei Zhang, Xiaozhong Chen, Qinjiang Liu, Song Qu, Jia Fan, Tianshu Liu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |